Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT07680790 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07680790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07680790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 3
Overall status
Recruiting
Start date
September 8, 2026
Completion date
December 30, 2031
Enrollment
850 (estimated)
Sites
201

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer